Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Wacker AG expands biotech business through €100m acquisition
Latest NewsMunich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.
BioBLU® Single-Use Bioreactors – Single-Use Simplicity
ProductsSingle-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Changes in the management of Abivax
AppointmentsThe French Abivax SA has had a new CEO since the beginning of May. Marc de Garidel took over the position and became interim chairman of the supervisory board.
Neogap Therapeutics AB partners with Cellerys AG
Latest NewsSwedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Conflict of interest?
OpinionIn 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which was accepted in Australia with the same data, PharmaMar sued the EC. European Biotechnology spoke with PharmaMar’s Chairman José María Fernández Sousa-Faro.
Dutch State to sell share capital of Intravacc BV
Latest NewsThe State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Immunology expert joins ImmunOs Therapeutics
AppointmentsThe biopharmaceutical company ImmunOs Therapeutics AG has appointed Michael A. Curran, PhD, as Chairman of the Company´s Scientific Advisory Board.
Tay Therapeutics in licensing deal with VYNE Therapeutics
Latest NewsTay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
Medigene licences CD40L-CD28 costimulatory switch receptor
Latest NewsGerman Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective.
EU to decarbonise aviation sector through green fuel targets
Latest NewsThe European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.